Aurora kinase B inhibitor AZD1152: repurposing for treatment of lupus nephritis driven by the results of clinical trialsResearch in context
Summary: Background: Lupus nephritis (LN) is one of the most common and severe complications of systemic lupus erythematosus (SLE). Multitarget therapy (MT) achieves a 20% higher complete remission (CR) rate compared to conventional therapy in LN management. Intrigued by its excellent clinical effi...
Saved in:
Main Authors: | Yue Zhao, Zuguo Zheng, Xuexiao Jin, Shaoshan Liang, Changming Zhang, Mingchao Zhang, Yue Lang, Ping Li, Zhihong Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-02-01
|
Series: | EBioMedicine |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352396424005899 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
TOPBP1 as a potential predictive biomarker for enhanced combinatorial efficacy of olaparib and AZD6738 in PDAC
by: Xiao-Mei Tang, et al.
Published: (2025-02-01) -
Machine Learning-Assisted Drug Repurposing Framework for Discovery of Aurora Kinase B Inhibitors
by: George Nicolae Daniel Ion, et al.
Published: (2024-12-01) -
Proteomic profiling identifies upregulation of aurora kinases causing resistance to taxane-type chemotherapy in triple negative breast cancer
by: Bohan Ning, et al.
Published: (2025-01-01) -
Asymptotic analysis of mathematical model describing a new treatment of breast cancer using AZD9496 and palbociclib
by: Ophir Nave, et al.
Published: (2025-01-01) -
Enhancement of CD8+T cell cytotoxicity activity by IFN-α implies alternative pathologic role in systemic lupus erythematosus
by: Chen-xing Zhang, et al.
Published: (2025-06-01)